This website is intended for UK healthcare professionals only
Prescribing information can be found here
Why invokana? for T2DM
Invokana Guideline Recommendations Icon

Guideline Recommendations

The latest ADA/EASD consensus report reminds us that the goal of treatment for Type 2 Diabetes Mellitus (T2DM) is to prevent or delay complications.

CKD or HF

  • For patients with T2DM where Chronic Kidney Disease (CKD) or Heart Failure (HF) predominates, an SGLT2i* shown to reduce CKD and/or HF progression in CVOTs if eGFR is adequate**, is preferable. 1
  • If SGLT2i not tolerated or contraindicated or if eGFR less than adequate add GLP-1 RA with proven CVD benefit*** 1

ASCVD

  • For patients with T2DM where atherosclerotic cardiovascular disease (ASCVD) predominates, a GLP-1 RA with proven CVD benefit is preferable*** 1
  • Or an SGLT2i with proven CVD benefit*** if eGFR is adequate** 1

*Empagliflozin, canagliflozin and dapagliflozin have shown reduction in HF and to reduce CKD progression in CVOTs.
**Be aware that SGLT2i labelling varies by region and individual agent with regard to indicated level of eGFR for initiation and continued use.
***Proven CVD benefit means it has label indication of reducing CVD events.

NICE/SIGN

  • The Scottish Intercollegiate Guidelines Network (SIGN) recommends SGLT2is, such as Invokana, as an option for add-on therapy to metformin, in addition to lifestyle measures, for patients with type 2 diabetes who do not achieve an HbA1c of <53 mmol/mol (7.0%) or individual target as agreed. 2
  • NICE also suggests SGLT2is, such as Invokana, as an option for dual therapy (i.e. at first intensification) for patients whose HbA1c rises to 58 mmol/mol (7.5%). 3
  • An SGLT2i, such as Invokana, can also be considered at second intensification as an add-on to other agents including sulphonylureas, thiazolidinediones and insulin. 3

Why choose Invokana?

Weight loss with Invokana is an additional benefit only and not a licensed indication.
References
  1. Reference 9
  2. Reference 6
  3. Reference 5
  4. Downey J. Pract Nurse. 2018; 48(1):12-16
  5. Neal B, et al. N Engl J Med. 2017; 377(7):644-57
  6. Silvio E, et al. Diabetologia. 2015; 58: 429-442
  7. Scirica B, et al. N Engl J Med. 2013; 369:1317-1326
  8. Rosenstock J, et al. JAMA. 2019; 321(1):69-79
  9. Marso S, et al. N Engl J Med. 2016; 375:1834-1844
  10. Green J, et al. N Engl J Med. 2015; 373:232-242
  11. White W, et al. N Engl J Med. 2013; 369:1327-1335
  12. Pfeffer M, et al. N Engl J Med. 2015; 373:2247-2257
  13. Marso S, et al. N Engl J Med. 2016; 375:311-322
  14. Holman R, et al. N Engl J Med. 2017; 377:1228-1239
  15. Dormandy J, et al. The Lancet. 2005; 366:1279-1289